miR-195 suppresses abdominal aortic aneurysm through the TNF-α/NF-κB and VEGF/PI3K/Akt pathway
- Authors:
- Published online on: January 25, 2018 https://doi.org/10.3892/ijmm.2018.3426
- Pages: 2350-2358
Abstract
Introduction
Abdominal aortic aneurysm (AAA) is a disease with a high mortality rate, which manifests as permanent abdominal aortic dilation with potential rupture and substantial hemorrhage, which eventually leads to patients succumbing to mortality (1,2). AAA ranks as the highest among all types of aneurysm in terms of morbidity rates. The disease is characterized by local and permanent dilation of the abdominal aortic wall, with the tumor body diameter being higher than normal; this leads to a weakened abdominal aortic wall, which is life-threatening once the tumor body ruptures (1,2).
AAA is currently considered to be associated with multiple factors, including heredity factors, biochemistry, immunity, inflammation and hemodynamics (3). The AAA continues to dilate until rupture when it occurs, and it is associated with a poor prognosis (3). Nuclear factor (NF)-κB p65 is a type of endonuclear transcription factor. The NF-κB p65 signaling pathway is important in regulating inflammatory, immune and cell apoptotic responses, the abnormal activation of which in the aorta promotes the expression of inflammatory factors and matrix mellatoproteinase (MMP)-hydrolyzed proteins, and becomes one of the factors inducing aneurysm genesis (4). Tumor necrosis factor (TNF)-α is an important pro-inflammatory cytokine, which is most closely associated with the genesis and development of AAA inflammation (5). It has been suggested that the level of TNF-α in the synovial fluid of patients with rheumatoid arthritis is positively correlated with the severity of AAA. Inhibiting the overexpression of TNF-α can prevent AAA, whereas antibody therapy targeting TNF-α can effectively alleviate AAA symptoms in patients and delay the progression of inflammation (6). TNF-α has been identified in in vitro experiments to induce the cell production of multiple inflammatory mediators, including interleukin (IL)-6, IL-8, prostaglandin E2, collagenase and metalloproteinase, promoting AAA inflammation and leading to articular damage (6).
MicroRNAs (miRNAs) are a type of highly conserved, small, non-coding RNA, which is distributed extensively in eukaryotes (7). They are also novel gene expression regulatory factors, which exert their function mainly through inhibiting target gene protein translation or degrading target mRNA (7). The majority of miRNAs in animals are considered to exert their functions through inhibiting post-transcriptional translation, whereas they function mainly through degrading target mRNAs in plants (8). miRNAs are involved in cell differentiation, proliferation and apoptotic processes; therefore, they are closely associated with multiple diseases, including tumors, cardiovascular diseases, fibrotic diseases and viral infections (9). Multiple miRNAs regulating extracellular matrix degradation and smooth muscle cell apoptosis have been identified in studies investigating the genesis and development of AAA in previous years. They are reported to potentially be involved in regulation (10). Zampetaki et al showed that miR-195 may contribute to the pathogenesis of AAA (11).
Vascular endothelial growth factor (VEGF) can promote endothelial formation and angiogenesis; however, it cannot enhance the proliferation of other cell types, which is an important characteristic of VEGF. In addition, VEGF can promote plasmin activity, prevent thrombosis, and increase capillary permeability and vasodilation. Therefore, VEGF is of significance in the repair of vascular injury and prevention of restenosis (12). It is known that the phosphoinositide 3-kinase (PI3K)/AKT signaling pathway is one of the important downstream signaling pathways of VEGF, which is involved in numerous processes, including tumor proliferation and metastasis (13). The PI3K/AKT signaling pathway is extensively distributed in cells, and is a signal transduction pathway involved in cell growth, proliferation, differentiation, cell survival, adhesion, migration and anti-apoptosis (14). Signaling pathways can regulate expression at the transcription level, promoting tumor angiogenesis. The aim of the present study was to identify the function of miR-195 on AAA and its possible mechanism.
Materials and methods
Ethics statement and patients
All experiments were approved by the Ethics Committee of the General Hospital of People's Liberation Army (Beijing, China). Whole blood samples from patients with AAA (n=6, 61.5±8.5 years old, male) and normal volunteers (n=6, 55.5±9.5 year age, male) were collected from General Hospital of People's Liberation Army (March and May 2015) and centrifuged at 1,000 × g for 10 min at 4°C. Serum was stored at −70°C for subsequent experiments.
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis
RNA was isolated from serum samples using TRIzol according to the manufacturer's protocol (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA). The RNA samples were first reverse transcribed with miRNA-specific primers, using a TaqMan miRNA reverse transcription kit (Invitrogen; Thermo Fisher Scientific, Inc.) in an iQ5 Real-Time PCR detection system (Bio-Rad Laboratories, Inc., Hercules, CA, USA). The StepOne Plus Real-Time PCR system (Applied Biosystems; Thermo Fisher Scientific, Inc.) was used to perform RT-qPCR using SYBR Green Supermix (Bio-Rad Laboratories, Inc.) according to the manufacturer's protocol. The following primers were used for the PCR: miR-195 forward, 5-GGGGAGCCAAAAGGGTCATCATCT-3′ and reverse, 5′-GAGGGGCCATCCACAGTCTTCT-3′; U6 forward, CTCGCTTCGGCAGCACA, and reverse, 5′-AACGCTTCACGAATTTGCGT-3′. The following thermocycling conditions were used for PCR: Initial at 95 °C for 5 min; 40 cycles of 95°C for 30 sec, 60°C for 30 sec and 72°C for 30 sec. The data were analyzed using the 2−∆∆Cq method (15).
Culture cell and transfection
Primary human umbilical vein endothelial cells (HUVECs; PromoCell GmbH, Heidelberg, Germany) were cultured in DMEM (Gibco; Thermo Fisher Scientific, Inc.) supplemented with penicillin/streptomycin (100 U/ml and 100 μg/ml), L-glutamine (2 mM) and FBS (10%, Thermo Fisher Scientific, Inc.) at 37°C in humidified air containing 5% CO2. The miR-195 mimics and negative mimics were obtained from iGene Biotechnology, Inc. (Shanghai, China). The cells were transfected with miR-195 mimics and negative mimics using Lipofectamine 2000 transfection reagent (Invitrogen; Thermo Fisher Scientific, Inc.) for 24 h. Subsequently, the cells (1×105 cell/well) were seeded in 6-well-plates and treated with 120 nM angiotensin II (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) for 20 h at 37°C, prior to treatment with 100 nM of lipopolysaccharide (LPS, Beyotime Institute of Biotechnology, Nanjing, China) for 4 h at 37°C.
ELISA
The supernatants of the cells were collected and the concentrations of IL-1β ELISA kit (cat. no. PI305) and IL-6 ELISA kit (cat. no. PI330) were assayed (both Beyotime Institute of Biotechnology). Absorbance detection was performed using a microplate reader (Bio-Rad Laboratories, Inc.) at 450 nm.
Western blot analysis
Total cellular lysates were prepared with radioimmunoprecipitation assay buffer, according to the manufacturer's protocol (Beyotime Institute of Biotechnology). The protein concentrations were determined using the Bicinchoninic Acid assay (Thermo Fisher Scientific, Inc.). Subsequently, 40 μg of the protein samples were separated by 8–12% SDS-PAGE and transferred onto a polyvinylidene fluoride membrane. The membrane was blocked with 5%- skim milk powder-TBST and western blot analysis was performed with the following primary antibodies: MMP-2 (cat. no. 40994, 1:2,000), MMP-9 (cat. no. 13667, 1:2,000), TNF-α (cat. no. 11948, 1:2,000), NF-κB (cat. no. 8242, 1:2,000), VEGF (cat. no. 9698, 1:2,000), PI3K (cat. no. PI3K, 1:2,000), p-Akt (cat. no. 4060, 1:1,000) and GAPDH (cat. no. 5174, 1:5,000, Cell Signaling Technology, Inc., Danvers, MA, USA) at 4°C overnight. Horseradish peroxidase-conjugated goat anti-mouse immunoglobulin G (cat. no. 7076, 1:5,000; Cell Signaling Technology, Inc.) was used as a secondary antibody at 37°C for 1 h and visualized using enhanced chemiluminescence detection (EMD Millipore, Billerica, MA, USA).
Statistical analysis
The results are expressed as the mean ± standard deviation and analyzed using SPSS 19.0 (IBM Corp., Armonk, NY, USA). Statistical analysis was performed using one-way analysis of variance followed by Bonferroni's post-hoc test. P<0.05 was considered to indicate a statistically significant difference.
Results
Expression levels of miR-195 in patients with AAA
With the aim of examining the miRNAs involved in the bone regeneration process of AAA, the present study analyzed the expression levels of miR-195 in patients with AAA and normal volunteers. As shown in Fig. 1A, the expression levels of miR-195 in patients with AAA were higher, compared with those in the normal volunteers. In the angiotensin II-induced cell model, the expression level of miR-195 was also increased, compared with that in the control group (Fig. 1B).
miR-195 promotes the levels of IL-1β and IL-6 in angiotensin II-vascular smooth muscle cells
In order to determine whether miR-195 affects inflammation in angiotensin II-vascular smooth muscle cells, the levels of IL-1β and IL-6 were examined for the array. As shown in Fig. 2A and B, miR-195 effectively increased the levels of IL-1β and IL-6 in the angiotensin II-vascular smooth muscle cells.
miR-195 promotes the protein expression of MMP-2 and MMP-9 in angiotensin II-vascular smooth muscle cells
To confirm the protein expression of MMP-2 and MMP-9 following induction of the overexpression of miR-195, the protein expression levels of MMP-2 and MMP-9 in the angiotensin II-vascular smooth muscle cells were measured. As shown in Fig. 3A–C miR-195 effectively promoted the protein expression levels of MMP-2 and MMP-9 in the angiotensin II-vascular smooth muscle cells.
miR-195 upregulates the protein expression of TNF-α and NF-κB in angiotensin II-vascular smooth muscle cells
To confirm the expression of inflammatory proteins in the AAA model, the protein expression levels of TNF-α and NF-κB were determined following the overexpression of miR-195. As shown in Fig. 4A–C, miR-195 significantly upregulated the protein expression of TNF-α and NF-κB in the angiotensin II-vascular smooth muscle cells.
miR-195 suppresses the protein expression of VEGF, PI3K and p-Akt in angiotensin II-vascular smooth muscle cells
To further elucidate the effect of miR-195 during AAA, the protein expression levels of VEGF, PI3K and p-Akt were determined in angiotensin II-vascular smooth muscle cells following the overexpression of miR-195. The protein expression levels of VEGF, PI3K and p-Akt in the angiotensin II-vascular smooth muscle cells were significantly downregulated by miR-195 (Fig. 5A–D).
TNF-α promotes the protein expression of TNF-α and NF-κB by miR-195
To characterize the effect of TNF-α on the function of miR-195 in AAA, the present study investigated the protein expression of TNF-α and NF-κB following treatment with miR-195 and TNF-α protein. As shown in Fig. 6A–C, the TNF-α recombinant protein significantly promoted the protein expression of TNF-α and NF-κB in the angiotensin II-vascular smooth muscle cells by miR-195. In addition, immunofluorescence was used to observe the protein expression of NF-κB in angiotensin II-vascular smooth muscle cells overexpressing miR-195. As shown in Fig. 7, the protein expression of NF-κB in the miR-195-overexpressing group was higher, compared with that in the control group, and the combination of miR-195 and TNF-α recombinant protein significantly increased the protein expression of NF-κB in the angiotensin II-vascular smooth muscle cells, compared with that in the miR-195 group.
TNF-α promotes the generation of IL-1β and IL-6 by miR-195
To confirm whether the levels of IL-1β and IL-6 induced by miR-195 were affected by TNF-α in AAA, the levels of IL-1β and IL-6 were quantified using ELISA kits. The increased levels of IL-1β and IL-6 in the angiotensin II-vascular smooth muscle cells induced by miR-195 were significantly promoted by the TNF-α recombinant protein (Fig. 8A and B).
TNF-α promotes the protein expression of MMP-2 and MMP-9 by miR-195
It was also found that TNF-α significantly promoted the protein expression of MMP-2 and MMP-9 by miR-195 in the angiotensin II-vascular smooth muscle cells (Fig. 9A–C). These data showed that miR-195/TNF-α affected inflammation in the development of AAA.
PI3K affects the protein expression levels of VEGF, PI3K and p-Akt by miR-195
The present study subsequently investigated whether PI3K was a potential target for miR-195 in the development of AAA. The PI3K inhibitor, LY294002, suppressed the PI3K signaling pathway in angiotensin II-vascular smooth muscle cells; the protein expression levels of VEGF, PI3K and p-Akt in the angiotensin II-vascular smooth muscle cells decreased by miR-195 were suppressed significantly by the PI3K inhibitor (Fig. 10A–D). It was found that miR-195 significantly suppressed the protein expression of VEGF in the angiotensin II-vascular smooth muscle cells, compared with that in the control group. The PI3K inhibitor led to significant suppression of the protein expression of VEGF in the angiotensin II-vascular smooth muscle cells with miR-195, compared with that in the miR-195 group without the inhibitor (Fig. 11).
PI3K affects the protein expression of MMP-2 and MMP-9 by miR-195
To determine whether miR-195 directly binds PI3K in the development of AAA, the protein expression levels of MMP-2 and MMP-9 were examined in angiotensin II-vascular smooth muscle cells. The PI3K inhibitor significantly induced the protein expression of MMP-2 and MMP-9 in the angiotensin II-vascular smooth muscle cells with miR-195, compared with that in the miR-195 group without the inhibitor (Fig. 12A–C).
Discussion
AAA is a serious, life-threatening vascular disease, which predominantly affects older men (15). Its morbidity rate has increased gradually, and it has become one of the top 10 causes of mortality in the elderly worldwide (15). Its risk factors include old age, being male, smoking, family history, central obesity, low high-density lipoprotein cholesterolemia and hypertension (15). AAA includes the following major pathogeneses: First is extracellular matrix degradation; extracellular matrix of the aorta is composed of collagen, elastin, fibronectin and laminin, which is the major component for maintaining the structural integrity and elasticity of vascular wall (15). Extracellular matrix degradation is mainly mediated by MMPs, among which, MMP-2 and MMP-9 are the most important and have been investigated extensively (2). The enhanced expression of MMP or reduced expression of its specific inhibitor induces increased MMP activity, which results in extracellular matrix degradation, loss of integrity and reduced elasticity of the vascular wall, eventually leading to aortectasia or aortic aneurysm formation (16). Second is smooth muscle cell apoptosis; it has been shown in human AAA tissue specimens that loss of smooth muscle cells in the tunica media is associated with smooth muscle cell apoptosis, and extracellular matrix degradation can lead to anoikis of smooth muscle cells (17). Third is inflammation, and fourth is angiogenesis. Angiogenesis is closely associated with the inflammatory response, and it the former is commonly considered an important factor promoting aortic rupture, whereas inflammation can regulate the genesis and development of AAA through stimulating angiogenesis (18). These important pathogeneses are closely associated, among which extracellular matrix degradation is the most important. In the present study, the expression levels of miR-195 were we analyzed in patients with AAA and were found to be higher, compared with those in normal volunteers. miR-195 effectively promoted the protein expression of MMP-2 and MMP-9 in angiotensin II-vascular smooth muscle cells. Cai et al also reported that miR-195 inhibited the tumor progression of prostate cancer via MMP-9 and VEGF (19).
miRNAs are a novel type of gene expression regulatory factor, which inhibits the translation process of mRNAs encoding proteins through binding with the target mRNA 3′untranslated region and inducing regulatory effects; it is also important in cell differentiation, proliferation, apoptosis and metabolism (20). Previously, it was found that multiple miRNAs are associated with the genesis and development of AAA, having regulatory effects on extracellular matrix degradation, vascular smooth muscle cell apoptosis, inflammation and angiogenesis (21). In the present study, it was found that miR-195 effectively increased the levels of IL-1β and IL-6 in angiotensin II-vascular smooth muscle cells. Chen et al reported that miR-195 suppressed ulcerative colitis-induced inflammation through targeting small mothers against decapentaplegic 7 (22).
NF-κB p65 predominantly exists in the cytoplasm in the form of an inactive precursor at rest. It can induce the expression of target genes once it is activated, including inflammatory mediators IL-1 and IL-6, and MMPs (23). Of these, the transcriptional activation of target MMP-2 and MMP-9 can lead to the degradation and destruction of abdominal aortic extracellular matrix (24). NF-κB inhibitor has been shown in animal experiments to significantly inhibit the formation of AAA (24). In addition, the present study demonstrated that miR-195 significantly upregulated the protein expression of TNF-α and NF-κB in angiotensin II-vascular smooth muscle cells. TNF-α promoted the pre-inflammatory effect of miR-195 on the protein expression of TNF-α and NF-κB, the levels of IL-1β and IL-6, and the protein expression of MMP-2 and MMP-9 in angiotensin II-vascular smooth muscle cells. Ding et al showed that miR-195 suppresses cancer cell proliferation and migration in hepatocellular carcinoma through the TNF-α/NF-κB pathway (25).
Angiogenesis refers to the process of growing new blood vessels from endothelial cells in original blood vessels through budding, migration and proliferation (12). VEGF can increase number of vesicles in endothelial cells as the most specific key precipitating factor of angiogenesis, which increases vascular permeability (12). VEGF is an agent with the highest selectivity in promoting endothelial cell mitosis; it can promote the proliferation of smooth muscle cells, epithelial cells and fibroblasts, and induce angiogenesis. It also stimulates endothelial cells to produce nitric oxide, thus exerting a function of vascular maintenance (26). VEGF binds with its receptor, releases multiple growth factors and cytokines, induces the proliferation and migration of endothelial cells, and eventually promotes angiogenesis (13). The present study demonstrated that miR-195 significantly downregulated the protein expression of VEGF in angiotensin II-vascular smooth muscle cells. Almeida et al suggested that miR-195 regulates important mechanisms for bone regeneration through the expression of VEGF (27).
PI3K and its downstream AKT constitute an important signaling pathway, which is termed the PI3K/AKT signaling pathway and is vital for the survival, differentiation, proliferation and apoptosis of cells (14). The association between PI3K and tumors is supported in numerous studies, and an imbalance of PI3K/AKT is involved in multiple human tumor diseases, including lung cancer, nasopharyngeal carcinoma, liver cancer, gastrointestinal cancer, breast cancer, ovarian cancer, renal carcinoma, prostate cancer, lymphoma, malignant glioma and medulloblastoma (28). The correlation between PI3K/AKT and non-tumor diseases, including hepatic fibrosis, Alzheimer's disease, diabetes and cardiovascular diseases, has gradually attracted attention (29). The present study found that miR-195 significantly downregulated the protein expression of PI3K and p-AKT in angiotensin II-vascular smooth muscle cells. The suppression of PI3K promoted the pre-inflammatory effect of miR-195 on the protein expression of PI3K, p-Akt and VEGF, levels of IL-1β and IL-6, and protein expression of MMP-2 and MMP-9 in angiotensin II-vascular smooth muscle cells. Sun et al indicated that miR-195 has a tumor suppressive effect in ACHN cells through the PI3K/Akt signaling pathways (30).
In conclusion, the present study demonstrated that miR-195 suppressed AAA through the TNF-α/NF-κB and VEGF/PI3K/Akt pathways (Fig. 13). Taken together, these observations revealed that miR-195 functioned as an anti-inflammatory in AAA through the TNF-α/NF-κB and VEGF/PI3K/Akt pathways.
Notes
[1] Competing interests
The authors declare that they have no competing interests.
References
|
Liu J, Zuo SW, Li Y, Jia X, Jia SH, Zhang T, Song YX, Wei YQ, Xiong J, Hu YH and Guo W: Hyperhomocysteinaemia is an independent risk factor of abdominal aortic aneurysm in a Chinese Han population. Sci Rep. 6:179662016. View Article : Google Scholar : PubMed/NCBI | |
|
Lindeman JH, Abdul-Hussien H, van Bockel JH, Wolterbeek R and Kleemann R: Clinical trial of doxycycline for matrix metalloproteinase-9 inhibition in patients with an abdominal aneurysm: Doxycycline selectively depletes aortic wall neutrophils and cytotoxic T cells. Circulation. 119:2209–2216. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Lindberg S, Zarrouk M, Holst J and Gottsater A: Inflammatory markers associated with abdominal aortic aneurysm. Eur Cytokine Netw. 27:75–80. 2016.PubMed/NCBI | |
|
Ciavarella C, Alviano F, Gallitto E, Ricci F, Buzzi M, Velati C, Stella A, Freyrie A and Pasquinelli G: Human vascular wall mesenchymal stromal cells contribute to abdominal aortic aneurysm pathogenesis through an impaired immunomodulatory activity and increased levels of matrix metalloproteinase-9. Circ J. 79:1460–1469. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Y, Ait-Oufella H, Herbin O, Bonnin P, Ramkhelawon B, Taleb S, Huang J, Offenstadt G, Combadière C, Rénia L, et al: TGF-beta activity protects against inflammatory aortic aneurysm progression and complications in angiotensin II-infused mice. J Clin Invest. 120:422–432. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Wang L, Wang B, Li H, Lu H, Qiu F, Xiong L, Xu Y, Wang G, Liu X, Wu H and Jing H: Quercetin, a flavonoid with anti-inflammatory activity, suppresses the development of abdominal aortic aneurysms in mice. Eur J Pharmacol. 690:133–141. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Biros E, Moran CS, Wang Y, Walker PJ, Cardinal J and Golledge J: microRNA profiling in patients with abdominal aortic aneurysms: The significance of miR-155. Clin Sci (Lond). 126:795–803. 2014. View Article : Google Scholar | |
|
Maegdefessel L, Azuma J and Tsao PS: MicroRNA-29b regulation of abdominal aortic aneurysm development. Trends Cardiovasc Med. 24:1–6. 2014. View Article : Google Scholar | |
|
Carvalho LS: Can microRNAs improve prediction of abdominal aortic aneurysm growth? Atherosclerosis. 256:131–133. 2017. View Article : Google Scholar | |
|
Spin JM and Tsao PS: Battle of the bulge: miR-195 versus miR-29b in aortic aneurysm. Circ Res. 115:812–813. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Zampetaki A, Attia R, Mayr U, Gomes RS, Phinikaridou A, Yin X, Langley SR, Willeit P, Lu R, Fanshawe B, et al: Role of miR-195 in aortic aneurysmal disease. Circ Res. 115:857–866. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Kaneko H, Anzai T, Takahashi T, Kohno T, Shimoda M, Sasaki A, Shimizu H, Nagai T, Maekawa Y, Yoshimura K, et al: Role of vascular endothelial growth factor-A in development of abdominal aortic aneurysm. Cardiovasc Res. 91:358–367. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Wolanska M, Bankowska-Guszczyn E, Sobolewski K and Kowalewski R: Expression of VEGFs and its receptors in abdominal aortic aneurysm. Int Angiol. 34:520–528. 2015.PubMed/NCBI | |
|
Yu B, Liu L, Sun H and Chen Y: Long noncoding RNA AK056155 involved in the development of Loeys-Dietz syndrome through AKT/PI3K signaling pathway. Int J Clin Exp Pathol. 8:10768–10775. 2015.PubMed/NCBI | |
|
Walsh SR, Sadat U, Boyle JR, Tang TY, Lapsley M, Norden AG and Gaunt ME: Remote ischemic preconditioning for renal protection during elective open infrarenal abdominal aortic aneurysm repair: Randomized controlled trial. Vasc Endovascular Surg. 44:334–340. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Karlsson L, Bergqvist D, Lindbäck J and Pärsson H: Expansion of small-diameter abdominal aortic aneurysms is not reflected by the release of inflammatory mediators IL-6, MMP-9 and CRP in plasma. Eur J Vasc Endovasc Surg. 37:420–424. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Bruegger D, Bauer A, Rehm M, Niklas M, Jacob M, Irlbeck M, Becker BF and Christ F: Effect of hypertonic saline dextran on acid-base balance in patients undergoing surgery of abdominal aortic aneurysm. Crit Care Med. 33:556–563. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Muehling BM, Ortlieb L, Oberhuber A and Orend KH: Fast track management reduces the systemic inflammatory response and organ failure following elective infrarenal aortic aneurysm repair. Interact Cardiovasc Thorac Surg. 12:784–788. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Cai C, Chen QB, Han ZD, Zhang YQ, He HC, Chen JH, Chen YR, Yang SB, Wu YD, Zeng YR, et al: miR-195 inhibits tumor progression by targeting RPS6KB1 in human prostate cancer. Clin Cancer Res. 21:4922–4934. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Wanhainen A, Mani K, Vorkapic E, De Basso R, Björck M, Länne T and Wågsäter D: Screening of circulating microRNA biomarkers for prevalence of abdominal aortic aneurysm and aneurysm growth. Atherosclerosis. 256:82–88. 2017. View Article : Google Scholar | |
|
Davis FM, Rateri DL and Daugherty A: Abdominal aortic aneurysm: Novel mechanisms and therapies. Curr Opin Cardiol. 30:566–573. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Chen G, Cao S, Liu F and Liu Y: miR-195 plays a role in steroid resistance of ulcerative colitis by targeting Smad7. Biochem J. 471:357–367. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Mi T, Nie B, Zhang C and Zhou H: The elevated expression of osteopontin and NF-kappaB in human aortic aneurysms and its implication. J Huazhong Univ Sci Technolog Med Sci. 31:602–607. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang F, Banker G, Liu X, Suwanabol PA, Lengfeld J, Yamanouchi D, Kent KC and Liu B: The novel function of advanced glycation end products in regulation of MMP-9 production. J Surg Res. 171:871–876. 2011. View Article : Google Scholar | |
|
Ding J, Huang S, Wang Y, Tian Q, Zha R, Shi H, Wang Q, Ge C, Chen T, Zhao Y, et al: Genome-wide screening reveals that miR-195 targets the TNF-alpha/NF-kappaB pathway by down-regulating IkappaB kinase alpha and TAB3 in hepatocellular carcinoma. Hepatology. 58:654–666. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Nishibe T, Dardik A, Kondo Y, Kudo F, Muto A, Nishi M, Nishibe M and Shigematsu H: Expression and localization of vascular endothelial growth factor in normal abdominal aorta and abdominal aortic aneurysm. Int Angiol. 29:260–265. 2010.PubMed/NCBI | |
|
Almeida MI, Silva AM, Vasconcelos DM, Almeida CR, Caires H, Pinto MT, Calin GA, Santos SG and Barbosa MA: miR-195 in human primary mesenchymal stromal/stem cells regulates proliferation, osteogenesis and paracrine effect on angiogenesis. Oncotarget. 7:7–22. 2016. View Article : Google Scholar : | |
|
Zhang S, Kan X, Li Y, Li P, Zhang C, Li G, Du J and You B: Deficiency of γδT cells protects against abdominal aortic aneurysms by regulating phosphoinositide 3-kinase/AKT signaling. J Vasc Surg. S0741–S5214(16): 31854–7. 2016. | |
|
Keppler-Noreuil KM, Parker VE, Darling TN and Martinez-Agosto JA: Somatic overgrowth disorders of the PI3K/AKT/mTOR pathway & therapeutic strategies. Am J Med Genet C Semin Med Genet. 172:402–421. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Sun P, Wang L, Lu Y, Liu Y, Li L, Yin L, Zhang C, Zhao W, Shen B and Xu W: MicroRNA-195 targets VEGFR2 and has a tumor suppressive role in ACHN cells via PI3K/Akt and Raf/MEK/ERK signaling pathways. Int J Oncol. 49:1155–1163. 2016. View Article : Google Scholar : PubMed/NCBI |
